Cyclospora Testing & Treatment Guidance

Cyclospora Testing & Treatment Guidance
07.16.2026

Healthy patients with cyclospora do not need to be tested or treated — there is no evidence that treatment shortens illness duration in otherwise healthy patients.

  • If you are caring for a healthy, immunocompetent patient who has symptoms that could be cyclosporiasis or another GI illness, please prescribe supportive care and recommend testing and treatment only if they meet the criteria listed below.

Testing and treatment criteria for Cyclospora:

  • Immunocompromised patients (IgA deficiencies, HIV, or immunosuppressing medication such as chemotherapy or disease-modifying anti-rheumatic drugs).
  • Infants and young children, pregnant women, and elderly patients (these patients may be at a higher risk for dehydration).
  • Immunocompetent patients with prolonged symptoms (longer than 14 days).

Empiric treatment is not recommended because while there is an outbreak in the State of Michigan, most patients with symptoms are more likely to be unrelated to cyclospora.

  • The only recommended exception is patients with prolonged symptoms (more than 14 days), severe symptoms (requiring IV fluids or admission), or highly immunocompromised patients. Treatment can be started for these patients once a stool specimen is obtained and sent for testing.

There are two tests that can be ordered through MHC to test for Cyclospora cayetanensis.

  • GI panel travel/parasite. This test is billed at $593 and has a turnaround time at 1-2 days. Reagent for this test is limited and we may need to delay some testing based on reagent supply. If this becomes necessary, we will share that information with you.
  • Cyclospora stain through Mayo Labs, for non-urgent patients: CYCL - Cyclospora Stain, Feces. This test is billed at $219, and results are expected within 4-5 days, although turnaround times may be delayed due to the outbreak.
    • Orderable is not available in MHC Laboratory Compendium, order as Mayo Miscellaneous Test with code CYCL.
    • Due to outbreak status testing is currently on a delay notice >4 days. See CYCL Test Delay Notice.
  • Stool cultures and traditional Ova & Parasite testing do not routinely detect Cyclospora cayetanensis.
  • Patients can be referred to any MHC laboratory for collection kit pick up and or specimen drop off. Please ensure a laboratory order requisition for testing is available.
  • Insurance coverage for testing varies. For an estimate, patients can call 231-935-6159.
  • Positive Cyclospora cayetanensis will be submitted to MDHHS per the reportable disease guide.
  • Testing reagent is limited. Further testing criteria may be applied, including Mayo Clinic send out for non-urgent cases.
  • For testing updates visit MHC Lab Test Catalog.

If treatment is indicated, the first line is trimethoprim-sulfamethoxazole (TMP-SMX) 

  • Adults: TMP-SMX 1 DS tab twice daily x 7 days.
    • Pregnancy risks: neural tube defects in 1st trimester pregnancy — if treatment benefit outweighs the risk, consider supplementation with folic acid 4mg daily during treatment course. Risk of jaundice and neonatal kernicterus if given at term.
    • Longer courses may be required for immunocompromised patients.
  • Infants ≥2 months, children, and adolescents (limited data available): 8 to 10 mg TMP/kg/day in divided doses every 12 hours; maximum dose: 160 mg TMP/dose. Typical treatment duration is 7 to 10 days. Longer courses may be required for immunocompromised patients.
  • If the patient has a sulfa allergy, ciprofloxacin or nitazoxanide are alternative treatments, but neither has shown high efficacy at reducing symptoms.